Processa Pharmaceuticals, Inc. filed Definitive Additional Materials (DEFA14A) on November 5, 2026, disclosing a stockholder letter explaining the July 2026 Vidya Therapeutics acquisition, the resulting capitalization structure, and the company's development plans for lead candidate VT-7208.

Key Highlights

  • Vidya acquisition and financing: Processa acquired Vidya Therapeutics in July 2026 and completed a concurrent private placement generating approximately $183.3 million in net proceeds, supported by institutional healthcare investors.
  • Funding runway: The July financing is expected to fund operations into the second half of 2029, according to the filing.
  • As-converted share count: Common shares currently outstanding total approximately 2.8 million; on an as-converted basis including Series A preferred stock, the total is approximately 309.3 million shares.
  • FDA IND clearance: The FDA cleared the IND application for the planned Phase 2 clinical trial of VT-7208 in Chronic Spontaneous Urticaria (CSU).
  • Three initial indications: VT-7208 is being advanced in food allergy, CSU, and relapsing multiple sclerosis.
  • Leadership additions: Dr. Sheila Gujrathi was appointed Executive Chair; Gregory J. Flesher, Craig Coburn Ph.D., Ashley Hall J.D., and Michael P. Cruse were added to the executive team.
  • Two special meetings: Definitive proxy materials for the first special meeting were filed October 22, 2026; materials for the second meeting are described as forthcoming.

Processa Outlines VT-7208 Strategy and Capital Structure Following Vidya Acquisition

According to the filing, Processa Pharmaceuticals (NASDAQ:PCSA) mailed a letter to stockholders on November 5, 2026, providing context for two upcoming special meetings at which stockholders will be asked to vote on several proposals. The letter describes the July 2026 acquisition of Vidya Therapeutics and an accompanying private placement of approximately $200 million, which the company disclosed established "a new strategic direction for the company focused on advancing differentiated therapeutic programs for immunological and inflammatory (I&I) diseases."

The filing states that the lead program, VT-7208, is "an oral, once-daily investigational product candidate that inhibits Bruton's tyrosine kinase, or BTK," and was designed to reach both the systemic immune system and the central nervous system. The company is advancing VT-7208 in three indications: food allergy, affecting approximately 17 million people in the United States including an estimated 3.6 million children; CSU, estimated to affect 1.6 to 2 million people in the United States; and relapsing multiple sclerosis, with an estimated 1 million affected people in the United States. The filing notes that the FDA has cleared the IND for the planned Phase 2 trial of VT-7208 in CSU.

The filing also describes a second pipeline program: a novel oral macrocyclic peptide-based neonatal Fc receptor (FcRn) antagonist being advanced through a research collaboration and exclusive option agreement with Generian Pharmaceuticals. On capitalization, the filing discloses that approximately 2.8 million common shares are currently outstanding, with Series A preferred stock convertible into approximately 306.5 million common shares on an as-converted basis, subject to stockholder approval and applicable beneficial ownership limitations. Stockholder votes are required, among other things, to permit conversion of the Series A preferred stock into common stock and to support continued compliance with Nasdaq listing standards.

What Was Disclosed

Processa Pharmaceuticals filed a stockholder letter as Definitive Additional Materials on November 5, 2026, disclosing details of the Vidya Therapeutics acquisition, VT-7208's development plan across three indications, net proceeds of approximately $183.3 million, expected as-converted capitalization of approximately 309.3 million shares, and two upcoming special stockholder meetings.